# Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

> **NCT05132088** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 201 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** semaglutide 50 mg
- **DRUG:** placebo (semaglutide)

## Key facts

- **NCT ID:** NCT05132088
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2023-07-11
- **Final completion:** 2023-09-01
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132088, "Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05132088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*